A Phase 1 interventional study of INT-1868 Tablets and INT-1868 Tablets in Atopic Dermatitis (AD), sponsored by Innatus Therapeutics (Shanghai) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Innatus Therapeutics (Shanghai) Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.
Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 136th largest by planned enrollment of the 191 interventional ones that give a count, is one of 33 that started in 2026, is one of 39 in phase 1, reaches primary completion later than 47 of the 82 other live ones, and was the 207th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Sites in China
Ages 18–75
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 2–11
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
QuantX Biosciences, Inc. · Sites in China
Ages 18 mo–65 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 54 · Phase 2 76 · Phase 3 63 · Phase 4 5
First in 2011; this study’s year is marked. 33 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 92 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 163 across the 191 interventional studies, 472 across the 16 observational. Of the 114 that completed or were terminated, 22 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 207 have an industry lead sponsor. The 10 most frequent:
Innatus Therapeutics (Shanghai) Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Innatus Therapeutics (Shanghai) Co., Ltd. has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
28 of the studies in Dermatitis, Atopic with a site in China that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06775860Phase 3Beijing InnoCare Pharma Tech Co., Ltd.ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | 2026-11-25 |
| NCT07540442Phase 3Shanghai Mabgeek Biotech.Co.LtdA Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-01-05 |
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
| NCT06880276Phase 3Qilu Pharmaceutical Co., Ltd.Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | 2027-03 |
| NCT07386743Phase 3Jiangsu Genscend Biopharmaceutical Co., LtdA Phase III Study of GS101 Injection to Dupixent® | 2027-04 |
Add all 28 to your calendar (.ics) → With an account.
Among the 207 studies in Dermatitis, Atopic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INT-1868 Tablets in Healthy Adult Participants.
Primary Objectives:
1. To evaluate the safety and tolerability of INT-1868 tablets after single and multiple doses in healthy adult participants;
Secondary Objectives:
1. To evaluate the PK characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants; 2. To evaluate the effect of food on the PK characteristics of INT-1868 tablets;
Other Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
During the screening period, the presence of any of the following electrocardiogram (ECG) abnormalities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Ascending Dose
Drug: INT-1868 Tablets
QD for 14 days;
Drug: INT-1868 Tablets
Drug: INT-1868 Tablets
Placebo for SAD, MAD and Food Effect
Drug: INT-1868 Placebo
Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration
Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration
100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration
INT-1868 Placebo;PO
Adverse events(AEs)
The incidence, severity and types of AES
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Laboratory tests: Complete Blood Count
Including complete blood count, blood biochemistry, coagulation function, and urinalysis
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Physical examination
Including general condition (skin and lymph nodes), head (eyes, ears, nose, and throat), neck (thyroid gland), chest (lungs and heart), abdomen, spine and extremities, and nervous system
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Treatment-emergent potentially clinically significant abnormalities in vital signs:blood pressure (mmHg)
Blood pressure (mmHg)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Treatment-emergent potentially clinically significant abnormalities in vital signs:pulse rate (bpm)
Pulse rate (bpm)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Treatment-emergent potentially clinically significant abnormalities in vital signs: respiratory rate (brpm)
Respiratory rate (brpm)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Treatment-emergent potentially clinically significant abnormalities in vital signs: body temperature (℃)
Body temperature (℃)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: heart rate (bpm)
Heart rate (bpm)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: PR Interval (milliseconds)
PR Interval (milliseconds)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: QRS duration (milliseconds)
QRS duration (milliseconds)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: QT interval (milliseconds)
QT interval (milliseconds)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
The main parameters of the 12-lead electrocardiogram (ECG) examination: QTc (milliseconds)
QTc (milliseconds)
Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
Pharmacokinetics parameter: Cmax of INT-1868
Maximum plasma concentration
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: Tmax of INT-1868
Time to reach maximum plasma concentration
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: AUC0-t of INT-1868
Area under the concentration-time curve from time 0 to the time of the last measurable concentration (t)
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: AUC0-24 of INT-1868
Area under the plasma concentration-time curve of the investigational product from 0 to 24 hours
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: AUC0-inf of INT-1868
Area under the plasma concentration-time curve of the investigational product from time 0 to infinity
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: t1/2 of INT-1868
Terminal elimination half-life
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: λz of INT-1868
Terminal elimination rate constant
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: CL/F of INT-1868
Apparent clearance
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: Vd/F of INT-1868
Apparent volume of distribution
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: tlag of INT-1868
Lag time
Time frame: SAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (15 blood sampling time points) FE:pre-dose (within 1 hour) and post-dose at 1~ 144 hours (30 blood sampling time points)
Pharmacokinetics parameter: Cmin,ss of INT-1868
Minimum plasma concentration at steady state
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Cmax,ss of INT-1868
Maximum plasma concentration at steady state
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Css,avg of INT-1868
Average plasma concentration at steady state
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: AUC0-t of INT-1868
Area under the plasma concentration-time curve of the investigational product during the dosing interval (t)
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Tmax of INT-1868
Time to reach maximum plasma concentration at steady state
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: λz of INT-1868
Terminal elimination rate constant
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: t1/2 of INT-1868
Terminal elimination half-life
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours(29 blood sampling time points)
Pharmacokinetics parameter: Rac(Cmax)of INT-1868
Accumulation ratio based on Cmax
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Rac(AUC)of INT-1868
Accumulation ratio based on AUC
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: CLss/F of INT-1868
Apparent clearance at steady state
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Pharmacokinetics parameter: Vz/F of INT-1868
Apparent volume of distribution at steady state
Time frame: MAD: pre-dose (within 1 hour) and post-dose at 1~ 144 hours (29 blood sampling time points)
Urinary pharmacokinetic parameters, including Ae and CumAe0-t, Fe, and CumFe0-tand CLr
Amount of drug excreted in urine (Ae), cumulative amount excreted in urine (CumAe0-t), urinary excretion fraction (Fe), cumulative excretion fraction (CumFe0-t) and renal clearance (CLr)
Time frame: SAD: pre-dose (-12 to 0 hours) and post-dose 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 24-48 hours, and 48-72 hours.
Fecal pharmacokinetic parameters, including Ae and CumAe0-t, Fe, and CumFe0-t
Amount of drug excreted in feces (Ae), cumulative amount excreted in feces (CumAe0-t), fecal excretion fraction (Fe), and cumulative excretion fraction (CumFe0-t)
Time frame: SAD: pre-dose (-24 to 0 hours) and post-dose 0-24 hours, 24-48 hours and 48-72 hours
Pharmacodynamics parameter: STAT6 of INT-1868
Signal transducer and activator of transcription 6 (STAT6) in peripheral blood
Time frame: SAD:pre-dose (within 1 hour) and post-dose from Day 1 to Day 14 MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 38
Pharmacodynamics parameter: TARC of INT-1868
Thymus and activation-regulated chemokine
Time frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
Pharmacodynamics parameter: IgE of INT-1868
Immunoglobulin E
Time frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
Pharmacodynamics parameter: Eotaxin-3 of INT-1868
Time frame: MAD: pre-dose (within 1 hour) and post-dose from Day 1 to Day 28
Pharmacodynamics parameter: STAT6 of INT-1868
STAT6 in skin tissue
Time frame: MAD: From Day-1 to Day 28
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 7 months is below that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innatus Therapeutics (Shanghai) Co., Ltd.